Related Experiment Videos
TGF-betas and TGF-beta receptors in atherosclerosis
1Weill Medical College of Cornell University, Department of Medicine, Division of Hematology/Oncology, New York, NY 10021, USA. tamccaf@med.cornell.edu
Abstract:
Based on diverse evidence in animals and humans, it has been hypothesized that atherosclerosis, and other injury-induced hyperplasias such as restenosis, may result from a failure in endogenous inhibitory systems that normally limit wound repair and induce regression of wound repair cells. A key defect in one of these inhibitory pathways, the TGF-beta system, has been identified and characterized in both animal models and in human lesions and lesion-derived cells. Cells derived from human lesions are resistant to the antiproliferative and apoptotic effects of TGF-beta, while their normal counterparts from the vascular media are potently inhibited and killed. Both cell types increase PAI-1 production, switch actin phenotypes in response to TGF-beta1, and produce similar levels of TGF-beta activity. Membrane cross-linking of (125)I-TGF-beta1 indicates that normal human SMC express Type I, II and III receptors. The Type II receptor is strikingly decreased in lesion cells, with little change in the Type I or III receptors. RT-PCR confirmed that the Type II TGF-beta1 receptor mRNA is reduced in lesion cells. Subsequent analysis of human lesion vs normal tissues confirmed that the Type I receptor was consistently present in the lesion, while the Type II receptor was much more variable, and commonly absent in both coronary artery and carotid artery lesions. Transfection of the Type II receptor into lesion cells partially restores the growth inhibitory response to TGF-beta1, implying that signaling remains intact. A subset of patients, and cells derived from their lesions, exhibit acquired mutations in the Type II receptor that would explain their resistance, though the majority of cells are resistant without obvious mutational defects. Thus, it is currently being tested whether transcriptional defects or abnormalities in receptor processing may explain the low levels of the Type II receptor. Because TGF-beta1 is overexpressed in fibroproliferative vascular lesions, receptor-negative cells would be allowed to grow in a slow, but uncontrolled fashion, while overproducing extracellular matrix components.
Insights
A defect in the transforming growth factor-beta (TGF-beta) system, specifically reduced Type II receptors, causes resistance to TGF-beta
Area of Science:
- Cardiovascular Biology
- Cellular Signaling
- Wound Healing Research
Background:
- Atherosclerosis and restenosis may stem from impaired endogenous inhibitory systems controlling wound repair.
- The transforming growth factor-beta (TGF-beta) system is a key inhibitory pathway implicated in these conditions.
- Human lesion-derived cells exhibit resistance to TGF-beta's normal inhibitory effects.
Purpose of the Study:
- To investigate the role of the TGF-beta system defect in atherosclerosis and restenosis.
- To characterize the specific alterations in TGF-beta receptors in human vascular lesions.
- To determine the functional consequences of these receptor alterations on cell behavior.
Main Methods:
- Analysis of TGF-beta signaling in cells derived from human vascular lesions versus normal vascular media.
- Assessment of TGF-beta receptor expression (Type I, II, III) using membrane cross-linking and RT-PCR.
- Functional studies involving transfection of TGF-beta Type II receptor into lesion cells.
- Examination of receptor expression in human coronary and carotid artery lesions.
Main Results:
- Lesion-derived cells are resistant to TGF-beta's antiproliferative and apoptotic effects, unlike normal cells.
- A significant decrease in TGF-beta Type II receptors, and corresponding mRNA, was observed in lesion cells.
- Normal cells express Types I, II, and III receptors, while lesion cells show reduced Type II receptor levels.
- Restoration of Type II receptor in lesion cells partially restored TGF-beta responsiveness.
- While some mutations exist, most resistance is linked to reduced Type II receptor levels, possibly due to transcriptional or processing defects.
Conclusions:
- Defects in the TGF-beta Type II receptor are a critical factor in the pathogenesis of atherosclerosis and restenosis.
- Reduced Type II receptor expression leads to uncontrolled cell growth and extracellular matrix overproduction in vascular lesions.
- Targeting TGF-beta signaling or receptor restoration may offer therapeutic strategies for fibroproliferative vascular diseases.